Links/Summaries of 3 Articles on Treatment of HCV

[Guest guest]

Telaprevir (Incivek) Approved in CanadaThe

hepatitis C virus (HCV) protease inhibitor telaprevir

(brand name Incivek) -- one of the first 2 direct-acting

antiviral drugs for genotype 1 chronic hepatitis C --

was approved in Canada this week. Telaprevir and another

HCV protease inhibitor, boceprevir (Victrelis), were approved

by the U.S. Food and Drug Administration (FDA) this past

May.Insulin Resistance Affects Sustained Response to

Hepatitis C TreatmentGreater insulin resistance was

association with poorer response to pegylated interferon

plus ribavirin regardless of hepatitis C virus (HCV)

genotype, according to a meta-analysis described in the

August 2011 issue of Alimentary Pharmacology and

Therapeutics.Epidemiology and Management of HCV Genotype

6Prevalence of hepatitis C virus (HCV) genotype 6 may be

as high as 50% in parts of Southeast Asia, according to

a systematic review published in the August 2011 issue

of Alimentary Pharmacology and Therapeutics. Compared

with genotypes 1 and 4, genotype 6 responds better to

interferon-based therapy.

[Guest guest]

Telaprevir (Incivek) Approved in CanadaThe

hepatitis C virus (HCV) protease inhibitor telaprevir

(brand name Incivek) -- one of the first 2 direct-acting

antiviral drugs for genotype 1 chronic hepatitis C --

was approved in Canada this week. Telaprevir and another

HCV protease inhibitor, boceprevir (Victrelis), were approved

by the U.S. Food and Drug Administration (FDA) this past

May.Insulin Resistance Affects Sustained Response to

Hepatitis C TreatmentGreater insulin resistance was

association with poorer response to pegylated interferon

plus ribavirin regardless of hepatitis C virus (HCV)

genotype, according to a meta-analysis described in the

August 2011 issue of Alimentary Pharmacology and

Therapeutics.Epidemiology and Management of HCV Genotype

6Prevalence of hepatitis C virus (HCV) genotype 6 may be

as high as 50% in parts of Southeast Asia, according to

a systematic review published in the August 2011 issue

of Alimentary Pharmacology and Therapeutics. Compared

with genotypes 1 and 4, genotype 6 responds better to

interferon-based therapy.